



“Celebrating 40 years of the BTS”
CONGRESS 2019

MONDAY 15th April 2019		
09:00	Registration open for CEP and Congress Delegates – <i>Dining Hall Balcony</i>	
09:00 – 12:00	UKEMS Committee Meeting – <i>Garden Room</i>	
11:30 – 12:30	BTS Scientific Subcommittee Meeting – <i>Seminar Room</i>	
Continuing Education Programme		
Genotoxicity Testing in the 21st Century – a Paradigm Shift! Chair: <i>Dr Jason Manton, Penman Consulting & Dr Julie Clements (Covance)</i> Auditorium Theatre		
09:30 – 10:00	<i>In silico</i> approaches to genotoxicity testing Dr Laura Brierley (Syngenta) - BTS	
10:00 – 10:30	Recent advances to <i>in vitro</i> gene toxicity testing Dr Ann Doherty (AZ) - UKEMS	
10:30 – 10:50	Refreshments <i>Dining Hall</i>	
10:50 – 11:20	New advances and assays in <i>in vivo</i> gene toxicity testing Jon Howe (GSK) - UKEMS	
11:20 – 11:50	Cross-industry view on genetic toxicity testing Tom Holmes (Adama) - BTS	
12:00 – 12.45	Lunch, & Trade Exhibition <i>Dining Hall</i>	
Congress Programme		
12:45 – 13:00	Congress Welcome BTS President: Dr Chris Powell (GlaxoSmithKline, Pharmaceuticals R&D) UKEMS President: Prof Karen Brown (<i>University of Leicester</i>) Auditorium Theatre	
13:00 – 14:00	Plenary Lecture: Impact of Artificial Intelligence in Understanding Toxicological Insights Dr Stefan Platz (AstraZeneca) Chair: <i>Dr Chris Powell (GlaxoSmithKline, Pharmaceuticals R&D)</i> Auditorium Theatre	
	Symposium 1: <i>Use of New Approach Methodologies in Regulatory Science</i> Chairs: <i>Dr Carol Courage (Boots) & Dr Camilla Alexander-White (Royal Society of Chemistry)</i> Auditorium Theatre	Symposium 2: <i>Developmental Toxicology: New paradigms</i> (Sponsored by the MHRA) Chairs: <i>Dr Henry Stemplewski & Dr David Jones (MHRA)</i> Umney Theatre
14:00 – 14:30	Using New Approach Methods in Regulatory Sciences Dr David Bell (European Chemical Agency)	Advances and challenges in risk assessment of germ cell mutagens in the 21st century Dr Francesco Marchetti (Health Canada)
14:30 – 15:00	New Approach Methodologies and Adverse Outcomes Pathways Dr Richard Currie (Syngenta)	Stem cell-based testing methods according to the AOP concept for developmental neurotoxicity(DNT) evaluation: are we there yet? Dr Ellen Fritsche (Leibniz Research Institute for Environmental Medicine, Düsseldorf)
15:00 – 15:30	Using New Approach Methodologies to underpin category approaches and read across in regulatory programmes Dr Hans Ketelslegers (CONCAWE)	Alternative approaches to DART assessment- an industry perspective Dr Kathryn Wolton (Syngenta, UK)

CONGRESS 2019

15:30 – 15:45	<u>Oral Communication</u> : Cosmetics Europe’s non-animal strategy: toxicokinetics for systemic toxicity assessment Dr Andreas Schepky (Beiersdorf AG)	<u>Oral Communication</u> : Human ES cell model for examining neurotoxicity in vulnerable neuronal populations Miss Emma Moles Garcia (MRC Toxicology Unit)
15:45 – 16:00	<u>Oral Communication</u> : New approach Methodologies in Read-Across: a workflow based on chemoinformatics Dr Elena Fioravanzo (ToxNavigation Ltd.)	<u>Oral Communication</u> : Can inducing phase 2 metabolism in the liver perturb thyroid homeostasis enough to cause adverse foetal neurodevelopment? Mr Terence Allen (Liverpool John Moores University)
16:00 – 16:15	Symposia Reflection and Discussion	Symposia Reflection and Discussion
16:15 – 16:45	<i>Refreshments, Posters & Trade Exhibition Dining Hall</i>	
	Symposium 3: MRC ITTP Biannual Symposium <i>Chairs: Prof Marion MacFarlane & Prof Andy Smith (MRC Toxicology Unit)</i> Auditorium Theatre	Symposium 4: New paradigms of genotoxicity safety evaluation for risk assessment <i>Chairs: Dr Julia Kenny (GSK) & Dr Patricia Parris (AstraZeneca)</i> Umney Theatre
16:45 – 17:15	Structural/functional insights into inhibitor and drug interactions with mitochondrial respiratory complex I Prof Judy Hirst (University of Cambridge)	Use of Duplex Sequencing™ for Detection of <i>In Vivo</i> Mutagenesis and early Preneoplastic Events as Biomarkers of Human Cancer Risk Bob Young (Bioreliance) <i>(Sponsored by MilliporeSigma/Merck)</i>
17:15 – 17:45	Post-transcriptional control of gene expression following toxic injury Prof Anne Willis (MRC Toxicology Unit)	Newly Validated 3D Skin Genotoxicity Assays Improve Safety Assessments of Cosmetic Ingredients Dr Stefan Pfuhrer (P&G)
17:45 – 18:15	The clinical toxicology of synthetic cannabinoids Dr Sally Bradberry (NPSU/West Mid Poisons Unit)	Novel extensions of the ToxTracker genotoxicity assay to provide insight into mode of action of aneugenic and clastogenic chemicals Dr Giel Hendriks (Toxys)
18:15 – 18:30	<i>Symposia Reflection & Discussion Session</i>	Genome-wide and gene-specific methylation assays to identify potential associations between de-methylating compounds and genotoxicity. Ms Rebekah Beck (University of Manchester)
18:30 – 20:00	BTS AGM: Auditorium Theatre	UKEMS AGM: Umney Theatre
20:00 onwards	BBQ & Drinks Reception <i>(Sponsored by ApconiX)</i> Crausaz Wordsworth Building	
20:30 onwards	Early Career Networking Session <i>(Sponsored by Unilever)</i> Crausaz Wordsworth Building	
20:30 onwards	BTS Executive Committee Meeting - Garden Room	


“Celebrating 40 years of the BTS”


CONGRESS 2019

TUESDAY 16th April 2019		
07:30 – 09:00	BTS Ambassadors Breakfast – TBC	
08:00	Registration opens - <i>Dining Hall Balcony</i>	
	Symposium 5: Cambridge Alliance on Medicines Safety (CAMS) <i>Chairs: Dr Muireann Coen (AstraZeneca) & Dr Jacqui Piner (CAMS)</i> Auditorium Theatre	Symposium 6: Mutational Signatures and DNA Repair <i>Chairs: Prof Simon Reed (Cardiff University) & Dr Ruth Morse (University of the West of England)</i> Umney Theatre
09:00 – 09:30	Computational approaches for predicting compound safety and toxicity – Methods and applications Dr Andreas Bender (Cambridge University)	53BP1 cooperation with the REV7-shieldin complex underpin DNA structure-specific NHEJ Dr Ross Chapman (University of Oxford)
09:30 – 10:00	The Safety Assessment of CRISPR Therapeutics Dr Mick Fellows (AstraZeneca)	INDUCE-Seq: detecting breaks in the thread of life. Prof Simon Reed (Cardiff University)
10:00 – 10:30	ImmuneMonitoring EBV reactivity in anti-CD3 mAb treated Type 1 diabetes patients Dr Andre van Maurik (GSK)	Histone Methylation by SETD1A Protects Nascent DNA through the Nucleosome Chaperone Activity of FANCD2 Prof Grant Stewart (University of Birmingham)
10:30 – 10:45	<u>Oral Communication:</u> Loss of IL6R causes immunodeficiency, atopy and abnormal inflammatory responses, and gives insight into toxicity of Tocilizumab Ms Sarah Spencer (University of Cambridge)	<u>Oral Communication:</u> Next Generation Sequencing (NGS) technologies and genetic toxicology Dr Anne Ashford (Astrazeneca)
10:45 – 11:00	<u>Oral Communication:</u> Qualification of cardiac cell models for preclinical predictive studies of drug-induced cardiotoxicity Ms Carol De Santis (Newcastle University)	<i>Symposia Reflection & Discussion Session</i>
11:00 – 11:15	<i>Symposia Reflection & Discussion Session</i>	
11:15 – 11:45	<i>Refreshments, Posters & Trade Exhibition Dining Hall</i>	
11:45 – 12:30	Early Career Investigator Prize Lecture: Deducing the particle lung-cell interaction: Advanced in vitro approaches Dr Martin Clift (Swansea University Medical School) <i>Chair: Dr J Gill (Newcastle University, UK)</i> Auditorium Theatre	
	RSC / BTS Selected Short Oral Communications <i>Chairs: Dr Sarah Judge (Newcastle University) & Dr Amy Wilson (AstraZeneca)</i> Auditorium Theatre	Study Director / Monitor Workshop 1 <i>Chairs: Sean O'Halloran (Covance) & Graham Morgan (ICON)</i> Umney Theatre
12:30 – 12:45	Protein targets associated with post-marketing adverse events of drugs Miss Ines Smit (University of Cambridge)	Case Study 1: Experience of setting up an in vivo capability at Gentronix Ltd. Julie Hayes (Gentronix Ltd)
12:45 – 13:00	Investigating the toxicity of modified therapeutic <i>in vitro</i> transcription (IVT) mRNA Mr Thomas Mulrone (MRC Toxicology Unit)	
13:00 – 13:15	Absence of metabolism-dependent toxicity of paracetamol in primary hepatocyte cultures Miss Lucia Livoti (University of Liverpool)	Case Study 2: Case studies on in vitro and in vivo genetic toxicology data Dr Jo Elloway (AstraZeneca)


“Celebrating 40 years of the BTS”


CONGRESS 2019

13:15 – 13:30	<p>Long-fibre carbon nanotubes induce pleural mesothelioma recapitulating human disease: A role for epigenetic mechanisms in disease development</p> <p>Dr Joaquin Zacarias Cabeza (MRC Toxicology Unit)</p>	Workshop Discussion Forum All participants
13:30 – 14:00	<p><i>Lunch (sponsored by Instem)</i></p> <p><i>Posters & Trade Exhibition Dining Hall</i></p>	Sponsored Lunchtime Workshop: Acea Biosciences Garden Room
14:00 – 14:30		
	<p>UKEMS Selected Short Oral Communications</p> <p><i>Chair: Dr Leanne Stannard (GSK) & Dr James Coulson (Cardiff University)</i></p> <p>Auditorium Theatre</p>	<p>Study Director / Monitor Workshop 2</p> <p><i>Chairs: Sean O’Halloran (Covance) & Graham Morgan (ICON)</i></p> <p>Umney Theatre</p>
14:30 – 14:45	<p>Development of the human PIG-A mutation assay as a blood-based biomarker for oesophageal adenocarcinoma.</p> <p>Miss Rachel Lawrence (Swansea University)</p>	<p>Case Study 3: A Few Days In The Life Of A Toxicology Study Director Paresh Masuria (GSK)</p> <p>Case Study 4: Potential limitations of “NOAEL”. Akin Akintomide (Envigo)</p>
14:45 – 15:00	<p>Redeployment: Assessing the potential of repurposed agents for mesothelioma chemoprevention.</p> <p>Miss Bethan Rogoyski (University of Leicester)</p>	
15:00 – 15:15	<p>Barcodes of Genotoxicity: Applying machine learning and artificial intelligence to Genotoxicity data.</p> <p>Dr Amy Wilson (Astrazeneca)</p>	
15:15 – 15:30	<p>Genotoxicity and cytokine secretion in co-cultured leukaemic and bone marrow stromal cells after cytarabine treatment</p> <p>Miss Liana Gynn (University of The West of England)</p>	Workshop Discussion Forum All participants
	<p>Roundtable Discussion:</p> <p>Auditorium / Garden Room / Seminar Room</p>	<p>UKEMS Regulatory updates.</p> <p><i>Chair: Dr Mick Fellows (AstraZeneca)</i></p> <p>Umney Theatre</p>
15:30 – 15:45	<p>Future Directions and Focus of BTS Speciality sub-sections – Why? What? When? How?</p> <p>Co-ordinators:</p> <p><i>Dr Muireann Coen (Discovery Toxicology section);</i></p> <p><i>Dr Henry Stemplewski (Regulatory section);</i></p> <p><i>Dr James Coulson (Clinical toxicology section);</i></p> <p><i>Dr Carol Courage (Risk assessment section);</i></p> <p><i>TBC (Computational and in silico toxicology section)</i></p>	<p>ICH S10 Phototoxicity</p> <p>Dr Daniel Bauer (Novartis)</p>
15:45 – 16:00		<p>ICH M7 Impurities</p> <p>Mrs Patricia Parris (AstraZeneca)</p>
16:00 – 16:15		
16:15 – 16:30		
16:30 -17:00		
17:00 – 17:30	<p><i>Refreshments, Posters & Trade Exhibition Dining Hall</i></p>	
17:30 – 18:30	<p>BTS: Barnes Prize Lecture:</p> <p>Toxicology concepts from applied and fundamental studies of iron and haem biology</p> <p>Professor Andy Smith (MRC Toxicology Unit)</p> <p><i>Chair: Dr Chris Powell (GlaxoSmithKline, Pharmaceuticals R&D)</i></p> <p>Auditorium Theatre</p>	
19:00 – 20:00	<p>Delegate Networking and Congress Dinner Drinks Reception</p> <p>Queens College</p>	
20:00 – Late	<p>Congress Dinner & Entertainment</p> <p>Queens College</p>	



“Celebrating 40 years of the BTS”
CONGRESS 2019

WEDNESDAY 17th April 2019		
08:00	Registration opens – <i>Dining Hall Balcony</i>	
	<p>Symposium 7: Alternative approaches to toxicology: What is the current view on the future of animal testing? (Sponsored by IVTS) <i>Chairs: Dr Martin Clift & Prof Gareth Jenkins (Swansea University)</i> Auditorium Theatre</p>	<p>Symposium 8: Oncology Combinations & DNA Damage Response <i>Chairs: Dr Sonja Gill & Dr Ann Doherty, (AstraZeneca)</i> Umney Theatre</p>
08:45 – 09:15	Usefulness of advanced in vitro models of the GI tract to study the genotoxicity of particulates Dr Roel Schins (IUF Leibniz, Germany)	Clinical scheduling and preclinical combinations Dr Mark O Connor (AstraZeneca)
09:15 – 09:45	Can human in silico drug trials replace the need for animal studies? Dr Elisa Passini (University of Oxford)	Advanced <i>in vitro</i> models of Hematopoiesis: the need, the vision- and applications in drug discovery process Dr Kainat Khan (AstraZeneca)
09:45 – 10:15	Alternatives in 21st century toxicology Prof Thomas Hartung (Johns Hopkins University, USA & University of Konstanz, Germany) <i>(German Toxicology Society invitation lecture)</i>	Pre-clinical and translational studies with the PARP inhibitors, focussing on rucaparib (Rubraca) Prof Nicola Curtin (Newcastle University)
10:15 – 10:30	<p><u>Oral Communication:</u> Can we use <i>in vitro</i> data to predict human hazard? A comparison of three evidence streams for troglitazone and rosiglitazone Dr Gerry Kenna (Safer Medicines Trust)</p>	<i>In vitro</i> and <i>in vivo</i> study of PIG-A assay in pancreatic cancer. Miss Lucy Nichols (Swansea University)
10:30 – 10:45		The effects of resveratrol on a mouse model of BRAF mutant colorectal carcinogenesis - a pilot proteomic study Miss Grandezza Aburido (University of Leicester)
10:45 – 11:00	Symposia Reflection and Discussion	Symposia Reflection and Discussion
11:00 – 11:30	<i>Refreshments, Posters & Trade Exhibition Dining Hall</i>	
11:30 – 12:15	<p>ASCEPT Lecture: Renal Transplantation: transporters, genetics and immunosuppressant nephrotoxicity Dr Benedetta Sallustio (Queen Elizabeth Hospital, Adelaide) <i>Chair: Dr John Thompson, Cardiff University</i> Auditorium Theatre</p>	
12:15 – 13:00	<i>Lunch, Posters & Trade Exhibition Dining Hall</i>	
13:00 – 14:00	<p>Workshop: Toxicology education in UK – Future Scope? <i>Chairs: Dr Jason Gill, Prof Ruth Roberts, Prof Gareth Jenkins</i> Auditorium Theatre & Umney Theatre</p>	
	<p>Symposium 9: Justification for Species Selection for Pharmaceutical Toxicity Studies (NC3Rs Sponsored) <i>Chair: Dr Catherine Ross (Covance) & Dr Fiona Sewell (NC3Rs)</i> Auditorium Theatre</p>	<p>Symposium 10: Health Impacts of Pollution <i>Chair: Dr Jill McKay (Northumbria University) & Prof Tim Gant (PHE & University of Surrey)</i> Umney Theatre</p>

CONGRESS 2019

14:00 – 14:30	NC3Rs/ABPI review of two species use: can we further exploit ICHS6 opportunities for one species? Dr Helen Prior (NC3Rs)	Air pollution exposure and new-born’s health: underlying modes of action Dr Nelly Saenen (Hasselt University, Belgium)
14:30 – 15:00	Are non-human primates (NHP) always the species of choice for development of biologics? Dr Alison Wolfreys (UCB)	Mutational signatures of environmental mutagens and chemotherapeutic agents Prof David Phillips (KCL)
15:00 – 15:15	When is the minipig the relevant non-rodent toxicology species? Dr Richard Haworth (GSK)	<u>Oral Communication</u> : Assessment of smoking habits of vape users, and the toxicity of nicotine based vape using a novel co-culture system. Dr Ruth Morse (University of The West of England)
15:15 – 15:30		<u>Oral Communication</u> : Measuring tumour response to chemotherapy using blood based biomarkers Ms Lucy Swithenbank (Swansea University)
15:30 – 15:45	Symposia Reflection and Discussion	<u>Oral Communication</u> : Differentiation of meningioma brain tissue using Raman hyperspectral imaging Mr Camilo de Lelis Medeiros-De-Morais (University of Central Lancashire)
15:45 - 16:00	<p align="center">Close of Congress BTS President: Dr Chris Powell (GlaxoSmithKline, Pharmaceuticals R&D) UKEMS President: Prof Karen Brown (<i>University of Leicester</i>) Auditorium Theatre</p>	
16:00	Refreshments Auditorium Foyer	